#MEDSIRatASCO
Dr. Tim Robinson breaks down the #WINBtrial, a study aiming to boost the effectiveness of sacituzumab/govitecan in breast cancer (TNBC & HR+). Despite its promise, many patients don't respond or progress quickly.

#MEDSIRatASCO
Day 4!
Isabel Tundidor shares how we combine hard work, science & collaboration during these intense (but rewarding) days.

👉🏼 www.youtube.com/shorts/Qxsac...

#ASCO25 #MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social

#GoodMorning MEDSIR
Today we're presenting the posters for #ADELAtrial and #WINBtrial in Hall A, from 9:00 to 12:00 (GMT-5).
📍 WINB: #479b
📍 ADELA: #103b

👉🏼 medsir.org/events/asco2...

#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social

#MEDSIRatASCO

Carmen Mora, from BD team, shares updates from day 2 at #ASCO25. Key meetings, global collaborations, and science in action. Let’s keep it going! 🚀

👉🏼 www.youtube.com/shorts/jcVK6...

#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social

#MEDSIRatASCO
On Day 1 of #ASCO25, one of the highlights for #MEDSIR was without a doubt the oral presentation of #TUXEDO3trial, exploring patritumab deruxtecan (HER3-DXd) in patients with very limited treatment options.

🎥 Watch Dr. Preusser explain more 👇
www.youtube.com/watch?v=bjyy...

#GoodMorning MEDSIR!
Day 2 at #ASCO25 kicks off with what drives us most: teamwork, planning, and purpose. Meetings, connections, and new opportunities await. Let’s go! 🚀

👉🏼 Stay tuned: lnkd.in/dkDs-bp4

#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social

#MEDSIRatASCO
Have you seen our exclusive newsletter from #ASCO25?
👉 Special Guest: Dr. Matthias Preusser
🗣️ Talking about #TUXEDO3trial, presented at
@ascocancer.bsky.social and published in Nature Medicine.

👉🏼 Click here and don’t miss it: www.linkedin.com/pulse/10-yea...

#MEDSIRatASCO
Major milestone at #ASCO25!
We presented the #TUXEDO3trial led by Dr. Matthias Preusser with Universität Wien as an oral presentation. The Phase II trial tested HER3-DXd in patients with brain mets & leptomeningeal disease.

#MEDSIRatASCO

Our BD Manager, Aurelio del Pino, shares how we're expanding at #ASCO25, connecting with key players & forging new partnerships to drive clinical research.

💬 Hit play & join us: medsir.org/events/asco2...

#MEDSIRLive #MedicalResearch #CancerCare #Innovation
@ascocancer.bsky.social

#MEDSIRatASCO
Educational sessions are underway and our team is already in Chicago! Want to meet with us at #ASCO25? Schedule your meeting here 👉 medsir.org/events/asco2...

#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social

#MEDSIRatASCO

@ascocancer.bsky.social 2025 kicks off today! We'll be sharing updates on #MEDSIR's participation in the most important oncology congress of the year.

Stay tuned! 👀

#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation

#MEDSIRatASCO is almost here!

Our Scientific Impact Manager, Jose Rodríguez Morató, has a quick message for you.

Let’s connect in Chicago and talk science!

More on our #ASCO25 plans 👉🏼 www.medsir.org/events/asco2...

#ASCO25 #MedicalResearch #CancerCare #Innovation